Clinical Trials Logo

Asthma clinical trials

View clinical trials related to Asthma.

Filter by:

NCT ID: NCT00094016 Completed - Asthma Clinical Trials

Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children

Start date: October 31, 2004
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the QVAR-Easi-Breathe 100 mcg/day and QVAR-Easi-Breathe 200 mcg/day with placebo relative to changes in forced expiratory volume in 1 second (FEV1) results following 12 weeks of treatment. Secondary objectives such as daily asthma symptoms scores (per week), morning peak expiratory flow (PEF) values, nocturnal awakening and utilization of rescue medication per day also will be evaluated. In addition, an exploratory evaluation will assess the comparability of the two devices (i.e., QVAR-Easi-Breathe versus QVAR-MDI) at the same dose levels.

NCT ID: NCT00092989 Completed - Asthma Clinical Trials

Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)

Start date: July 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate improved results of treatment for patients entering an emergency department with asthma attacks when given an investigational IV administration of an approved drug (MK-0476, montelukast sodium) in addition to approved standard treatment.

NCT ID: NCT00092885 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)

Start date: March 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effect of an approved medication on the symptoms of seasonal allergic rhinitis (a seasonal variety of inflammation of the mucous membrane of the nose) in patients who are experiencing symptoms of seasonal allergic rhinitis and asthma.

NCT ID: NCT00092144 Completed - Asthma Clinical Trials

Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)

Start date: February 26, 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of an approved drug on asthma symptoms in patients with chronic asthma which is also active during the allergy season.

NCT ID: NCT00092105 Completed - Clinical trials for Rhinitis, Allergic, Perennial

Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)

Start date: April 1, 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.

NCT ID: NCT00092092 Completed - Asthma, Bronchial Clinical Trials

Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)

Start date: October 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effect of montelukast, an approved medication, on the lower leg growth rate in children with mild asthma. The primary hypothesis is that the lower leg length (LLL) growth rate for children treated with montelukast compared to placebo will be established.

NCT ID: NCT00091767 Completed - Asthma Clinical Trials

Genetic Studies in Difficult to Treat Asthma: TENOR

Start date: September 2004
Phase: N/A
Study type: Observational

To investigate genetic factors that affect asthma severity.

NCT ID: NCT00090740 Completed - Asthma Clinical Trials

Genetic Risk Factors for Severe Asthma

Start date: September 2004
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether a specific genetic factor influences the severity of asthma symptoms.

NCT ID: NCT00088257 Completed - Asthma Clinical Trials

Maternal Fatty Acids, Child Obesity, and Asthma Immunity

Start date: August 2004
Phase: N/A
Study type: Observational

To study pre- and post-natal influences on the development of childhood asthma-related immune responses.

NCT ID: NCT00079937 Completed - Asthma Clinical Trials

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

Start date: April 2004
Phase: Phase 3
Study type: Interventional

A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks. In patients with allergies, there is an exaggerated production of IgE in response to specific substances such as pollens. Omalizumab is a new drug that inactivates IgE. This study tested the safety and efficacy of omalizumab against asthma attacks in children with allergic asthma.